Compare CDMOs with sterile injectable manufacturing capabilities. Filter by container type, aseptic technology, and regulatory approvals.
283 companies listed
Sterile injectable manufacturing produces parenteral drug products -- formulations administered by injection (intravenous, subcutaneous, intramuscular, intrathecal). These products require the highest level of manufacturing control because they bypass the body's natural defense barriers. Any microbial, particulate, or endotoxin contamination can be life-threatening.
The sterile injectable market is growing faster than overall pharma, driven by biologics (monoclonal antibodies, ADCs), specialty injectables (long-acting formulations, complex generics), and the shift toward self-administered subcutaneous products. Capacity remains constrained globally, with lead times of 12-24 months at many CDMOs.
Austria
Pharmazeutische Fabrik Montavit GmbH is an Austrian family-owned pharmaceutical company founded in 1945 in Absam, Tyrol. The company researches, develops, and manufactures pharmaceutical products and medical devices, exporting to over 80 countries. Montavit offers contract manufacturing (Lohnherstellung/Auftragsfertigung) services to other pharmaceutical companies. Dosage forms include tablets, film-coated tablets, dragees, liquids, creams/gels, granulates, suppositories, sterile pre-filled syringes, laminate tubes, sterile blisters, and powders. The company's own product portfolio covers urology, gynecology, allergy, sleep, travel health, and herbal medicines, with the wound care product Acerbine being well-known.
United States
Our AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.
Phlow Corporation is a U.S.-based public-benefit pharmaceutical manufacturer specializing in onshore continuous-flow production of medicines and APIs. The company was awarded a landmark $354 million HHS/ASPR/BARDA contract to manufacture essential medicines in shortage, strengthening America's pharmaceutical supply chain. Phlow has raised $37 million in Series C funding to expand U.S.-based CDMO operations. The company partners with Fresenius Kabi for the first-ever end-to-end U.S. manufacturing of Epinephrine Injection USP, with Antheia for advanced manufacturing technologies, and with USP for pharmaceutical continuous manufacturing. Phlow is driving sustainable cost competitiveness through advanced manufacturing technology including continuous flow chemistry and AI-enhanced analytics.